Are Manugraph India Ltd latest results good or bad?

Feb 11 2026 07:34 PM IST
share
Share Via
Manugraph India Ltd's latest results show significant year-on-year growth in net sales and a return to profitability, but ongoing operational challenges and declining profit margins raise concerns about long-term sustainability. Overall, while there is positive momentum, critical issues remain.
Manugraph India Ltd's latest financial results present a complex picture of recovery and ongoing challenges. In the quarter ending December 2025, the company reported net sales of ₹17.69 crores, reflecting a significant year-on-year growth of 175.98%. This growth is notable compared to the previous year's decline, indicating a strong rebound in revenue generation. Additionally, the standalone net profit for the same period reached ₹0.44 crores, marking a turnaround from a loss in the prior year, with a growth of 109.67%.
However, while the revenue and profit figures suggest positive momentum, the operational metrics reveal persistent issues. The operating profit margin, excluding other income, was reported at 5.88%, which indicates a substantial decline compared to the previous year, underscoring ongoing operational inefficiencies. Furthermore, the company continues to grapple with negative operating margins over the longer term, which raises concerns about its ability to achieve sustainable profitability. The financial performance over the nine-month period ending December 2025 shows a profit after tax of ₹4.89 crores, indicating a significant improvement from historical losses. This turnaround is a positive development, yet it is juxtaposed against the backdrop of structural weaknesses in the business model, as evidenced by negative return ratios and high operational costs relative to revenue. Overall, Manugraph India Ltd's recent results highlight a notable recovery in sales and profitability in the short term, but the company faces critical operational challenges that could hinder its long-term viability. The company saw an adjustment in its evaluation, reflecting these mixed operational trends and financial outcomes.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
Bharat Rasayan Ltd is Rated Strong Sell
10 minutes ago
share
Share Via
Epigral Ltd is Rated Sell
10 minutes ago
share
Share Via
Julien Agro Infratech Ltd is Rated Sell
10 minutes ago
share
Share Via
Zensar Technologies Ltd is Rated Sell
10 minutes ago
share
Share Via
Tatva Chintan Pharma Chem Ltd is Rated Hold
10 minutes ago
share
Share Via
Gufic BioSciences Ltd is Rated Strong Sell
10 minutes ago
share
Share Via